| Project/Area Number |
15K09339
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | University of Toyama (2016-2017)
Osaka University (2015) |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
奥野 龍禎 大阪大学, 医学系研究科, 助教 (00464248)
甲田 亨 大阪大学, 医学部附属病院, 医員 (70626134)
南波 明子 大阪大学, 医学部附属病院, 医員 (80774504)
山下 和哉 大阪大学, 医学部附属病院, 医員 (40774518)
|
|---|
| Project Period (FY) |
2015-10-21 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | PET / 酢酸 / アストロサイト / 多発性硬化症 / NMO / バイオマーカー / NMOSD / 高次脳機能障害 |
|---|
| Outline of Final Research Achievements |
To distinguish NMO and MS is clinically important because the prophylactic treatments are different for each disease. We have been working to establish 11C-acetate PET as a novel imaging biomarker to distinguish those two diseases. Ten healthy controls, 11 MS patients, and 12 NMOSD patients were enrolled, and we found that astrocytic metabolism is activated in the brain with MS, while it is decreased in the brain with NMO. Thus, it is expected that we can utilize 11C-acetate PET as a novel imaging biomarker for the differential diagnosis of MS and NMOSD.
|
